Short answer
BridgeBio Pharma, Inc. (BBIO) filed an 8-K current report with the SEC on May 27, 2026 reporting Item 8.01 (Other Events). FDA accepted BBP-418’s NDA for LGMD2I/R9, advancing the therapy into regulatory review.
BridgeBio Pharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA accepted BBP-418’s NDA for LGMD2I/R9, advancing the therapy into regulatory review
- Priority Review designation may accelerate FDA’s decision timeline for BBP-418
- Regulatory milestone could materially affect BBIO’s development outlook and valuation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BridgeBio Pharma, Inc. 8-K filings
Get the next BBIO 8-K as it lands
Follow BBIO for push alerts, or ask the research agent what this filing means.